Voyager Therapeutics Reports Q3 Earnings with EPS Beat but Revenue Miss
Voyager Therapeutics (VYGR) reported third-quarter financial results characterized by a narrow beat on earnings per share despite a significant revenue miss. The company posted a GAAP EPS of -$0.40, exceeding analyst expectations by $0.02. However, quarterly revenue fell to $4.01 million, representing a 70% year-over-year decline and missing estimates by $2.34 million. As of September 30, 2026, the company maintained a strong liquidity position with $132.1 million in cash, cash equivalents, and marketable securities. The substantial revenue drop reflects the ongoing nature of its clinical-stage operations, where income is often driven by non-recurring collaborations rather than consistent product sales.
Tickers: $VYGR
Topics: cash runway earnings beat financial results revenue miss